MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system

MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system

(2015) Gustavo Tapia et al.   APMIS

Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma

(2015) Stephan Kreher et al.   NEURO-ONCOLOGY

Overexpression of sphingosine-1-phosphate receptor 1 and phospho-signal transducer and activator of transcription 3 is associated with poor prognosis in rituximab-treated diffuse large B-cell lymphomas

(2014) Jin Ho Paik et al.   BMC CANCER

LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma

(2014) Chen Lossos et al.   BRITISH JOURNAL OF HAEMATOLOGY

Scoring of MYC protein expression in diffuse large B-cell lymphomas: concordance rate among hematopathologists

(2014) Amer Z Mahmoud et al.   MODERN PATHOLOGY

MYC Protein Expression in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

(2014) Kamraan Z. Gill et al.   PLoS One

Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYClowBCL2low subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas

(2013) Anna Brunn et al.   ACTA NEUROPATHOLOGICA

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

(2013) S. Hu et al.   BLOOD

Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202)

(2013) James L. Rubenstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2012) Tina Marie Green et al.   JOURNAL OF CLINICAL ONCOLOGY

Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2012) Nathalie A. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Activated B-cell immunophenotype might be associated with poor prognosis of primary central nervous system lymphomas

(2011) S. Bhagavathi et al.   CLINICAL NEUROPATHOLOGY

Prognostic value of immunohistochemical profile and response to high-dose methotrexate therapy in primary CNS lymphoma

(2009) Hiroyuki Momota et al.   JOURNAL OF NEURO-ONCOLOGY

Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases

(2009) Eyas M Hattab et al.   MODERN PATHOLOGY

Primary central nervous system lymphoma: Immunohistochemical profile and prognostic significance

(2009) Delphine Raoux et al.   NEUROPATHOLOGY

MYCtranslocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type

(2008) S O Yoon et al.   HISTOPATHOLOGY